News for Leica BOND-III
Leica Microsystems Launches the First Fully Automated One-step Dual Chromogen IHC Detection System for Use With Antibody Cocktails
The first fully automated one-step detection system allowing the co-visualization of mouse and rabbit antibodies on a single slide
18 November 2011
User Validated Prostate Marker Cocktail - P504S (Red) and HMW CK (DAB). Digital image captured using the Leica SCN400 Slide Scanner
Leica Microsystems announced today the availability of Leica ChromoPlex™ 1 Dual Detection for BOND, the first fully automated one-step detection system allowing the co-visualization of mouse and rabbit antibodies on a single slide. Same day diagnosis is now easier to achieve when compared with the two-step sequential or semi-automated processes currently available on competitive IHC advanced stainers. Developed for use with commercial and self-validated cocktails, ChromoPlex delivers the intense staining and clear background that BOND users currently enjoy from Leica’s Compact Polymer technology.
“When tissue is limited and diagnostic decisions are needed, the most effective use of tissue sections becomes imperative” comments Konstantin Fiedler, Vice President of Advanced Staining for Leica Microsystems. “The turnaround times achievable with our new ChromoPlex range open the door to faster patient management, while maintaining the diagnostic confidence pathologists demand to make the right decisions. Laboratories can choose antibodies from different sources, ensuring the most effective combinations of antibodies to aid diagnosis can always be used”.
“The dual staining obtained using the ChromoPlex 1 detection system is attractive, crisp and consistent; ideal when assessing challenging prostatic biopsies,” states Dr Geoffrey Hulman MD FRCPath, Consultant Histopathologist at Nottingham University Hospitals NHS Trust, where the detection technology was evaluated in cooperation with the Nottingham Health Science Biobank. Dr Claire Hawkes PhD, CSci comments that “historically, we encountered problems with dual staining and efforts to stain up commercial cocktails have been largely unsuccessful. The ChromoPlex 1 detection system, however, enables quick easy staining of both commercial and in-house home-brew cocktails, with excellent results.”
ChromoPlex 1 Dual Detection is a biotin-free, polymeric horseradish peroxidase (HRP)-linker and polymeric alkaline phosphatase (AP)-linker antibody conjugate system for the detection of tissue-bound mouse and rabbit IgG primary antibodies. The small multifunctional linkers enhance tissue penetration, producing high sensitivity. The excellent contrast between the Fast Red and DAB chromogens allows for easy antigen differentiation.
ChromoPlex 1 Dual Detection for BOND is intended for staining sections of formalin fixed, paraffin-embedded tissue for use on Leica BOND-MAX and BOND-III automated IHC staining systems. It can be used simultaneously with both Novocastra BOND Polymer Refine and Polymer Refine Red Detection, allowing unparalleled flexibility in staining protocols and workflow efficiency.
ChromoPlex 1 Dual Detection for BOND will be available for sale from December 1, 2011 in the United States of America, Canada, and the European Union.
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Leica Microsystems is a world leader in microscopes and scientific instruments. Founded as a family business in the nineteenth century, the company’s history was marked by unparalleled innovation on its way to becoming a global enterprise.
Its historically close cooperation with the scientific community is the key to Leica Microsystems’ tradition of innovation, which draws on users’ ideas and creates solutions tailored to their requirements. At the global level, Leica Microsystems is organized in four divisions, all of which are among the leaders in their respective fields: the Life Science Division, Industry Division, Biosystems Division and Medical Division.
Leica Microsystems’ Biosystems Division, also known as Leica Biosystems, offers histopathology laboratories the most extensive product range with appropriate products for each work step in histology and for a high level of productivity in the working processes of the entire laboratory.
The company is represented in over 100 countries with 12 manufacturing facilities in 7 countries, sales and service organizations in 19 countries and an international network of dealers. The company is headquartered in Wetzlar, Germany.
Leica BOND Data Update
v35 - Relevant for software version 4.0 and above
10 October 2011
Leica BOND Software Update
IMPORTANT
- This Leica BOND data update v35 is relevant for BOND software versions 4.0 and above only.
- This data update cannot be applied to earlier versions of the Bond software.
Please contact your local Leica Sales or Support representative to obtain the latest version.
Leica BOND-III Wins 2011 Medical Design Excellence Award
Innovative design that provides results 50% faster than previous-generation instruments
20 April 2011
Leica BOND-III wins 2011 MDEA
Melbourne, Australia. The Leica BOND-III instrument, a fully automated immunohistochemistry (IHC) and in situ hybridization (ISH) staining system used in cancer and infectious diseases diagnosis, has been awarded the prestigious Medical Design Excellence Award (MDEA) for its innovative design that provides results 50% faster than previous-generation instruments.
The MDEA competition is the premier worldwide awards program for the medical technology community. It recognizes the achievements of medical device manufacturers and suppliers who are responsible for creating innovative products that are changing the face of healthcare.
Leica BOND-III uses unique automation systems and advanced software to significantly reduce protocol run times, achieve high throughput and improve laboratory efficiency. Together, these advances help laboratories deliver critical results sooner and at lower costs. Chris Rhoades, Global Product Manager for Leica BOND Systems said, “Waiting for test results can be stressful for patients. By reducing this time, the Leica BOND-III instrument reduces the anxiety of patients and their families, and enables quicker access to the correct treatment for life threatening diseases.”
Designed for Lean Histology, the Leica BOND-III instrument helps diagnostic laboratories facing increased pressure to process greater numbers of patient samples with no corresponding budget or staff increases. The labor savings afforded by Leica BOND-III automation free technicians to perform other tasks while decreased run times allow additional tests to be performed each day. Leica BOND-III further improves laboratory operation by reducing maintenance, waste disposal costs and environmental impact. Also, by providing the ideal mix of scheduling flexibility and case organization, the system’s unique three-tray continuous processing capability helps optimize laboratory workflow. Combined, these benefits help laboratories meet increasing workloads using existing resources while both saving time and reducing costs.
The MDEA will be officially presented in a ceremony at the Medical Design & Manufacturing East 2011 Conference and Exposition in New York in June 2011. Representatives from Leica Microsystems and their design partner Invetech will be present to receive the award.
Leica Microsystems is a world leader in microscopes and scientific instruments. Founded as a family business in the nineteenth century, the company’s history was marked by unparalleled innovation on its way to becoming a global enterprise.
Its historically close cooperation with the scientific community is the key to Leica Microsystems’ tradition of innovation, which draws on users’ ideas and creates solutions tailored to their requirements. At the global level, Leica Microsystems is organized in four divisions, all of which are among the leaders in their respective fields: the Life Science Division, Industry Division, Biosystems Division and Medical Division.
Leica Microsystems’ Biosystems Division, also known as Leica Biosystems, offers histopathology laboratories the most extensive product range with appropriate products for each work step in histology and for a high level of productivity in the working processes of the entire laboratory.
The company is represented in over 100 countries with 12 manufacturing facilities in 7 countries, sales and service organizations in 19 countries and an international network of dealers. The company is headquartered in Wetzlar, Germany.
Sheron Lear: 50 years of service to histology
Much has changed in histology over the last 50 years, and one person has seen it all.
13 January 2011
Sheron Lear, Manager of Immunohistochemistry (IHC) at the CPA Laboratory in Louisville, Kentucky, USA
This year Sheron Lear celebrated half a century in the laboratory, and Leica Microsystems recently had the honor to spend time with her discussing the enormous advancements she has been part of.
As Sheron reaches her 50th year in histology, she continues to pursue scientific excellence and to improve the practice of histology. As Sheron admits, “the field has changed, I have changed” but she continues to search for improvements to the practice simply because, “I love it”.
Please click on the above hyperlink to read Sheron's story.
Click here to learn about Sheron's experiences with BOND III™ and BOND ready-to-use antibodies.
Sheron Lear on Leica BOND III™ and Leica BOND RTUs: “Phenomenal”
“To me the beauty of the BOND is the perfect consistency.”
13 January 2011
Sheron with the Leica BOND III system
After 50 years in histology, science veteran Sheron Lear has “seen a half century of technical change” in the preparation and examination of stains.
From the early days of manual preparation to today, Sheron shares her experiences on how laboratory efficiency has improved, especially since adopting Leica Microsystems’ BOND III and BOND ready-to-use antibodies (RTUs).
Click on the link above to read the full article about Sheron's experiences.